辅助中国传统中医治疗改善肝癌患者的生存期

StephenW

Adjunctive Traditional Chinese Medicine Therapy Improves Survival of Liver Cancer Patients

    Yueh-Hsiang Liao1,2, Cheng-Chieh Lin3,4,5, Hsueh-Chou Lai4,6, Jen-Huai Chiang7,8,9, Jaung-Geng Lin1,* andTsai-Chung Li8,9,10,*

DOI: 10.1111/liv.12847

This article is protected by copyright. All rights reserved.

Issue
Cover image for Vol. 35 Issue 5
Liver International


    1    School of Chinese Medicine, China Medical University, Taichung, Taiwan
    2    School of Chinese Medicine for Post-Baccalaureate, I-Shou University, Kaohsiung, Taiwan
    3    Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan
    4    School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan
    5    Department of Medical Research, China Medical University Hospital, Taichung, Taiwan
    6    Division of Hepatogastroenterology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan
    7    Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan
    8    Research Center for Chinese Medicine & Acupuncture, China Medical University, Taichung, Taiwan
    9    Graduate Institute of Biostatistics, China Medical University, Taichung, Taiwan
    10    Department of Healthcare Administration, College of Medical and Health Science, Asia University, Taichung, Taiwan

* Correspondence to: Tsai-Chung Li and Jaung-Geng Lin
China Medical University, 91 Hsueh-Shih Road, Taichung, 40402, Taiwan, Tel: 886-4-2205-3366 ext. 6605, Fax: 886-4-2207-8539, e-mail: [email protected]

    This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/liv.12847

Abstract
Background

Traditional Chinese medicine (TCM) is an alternative treatment for cancer with its effect by stimulating host immune response for cytotoxic activity against liver cancer. No studies evaluated TCM treatment on survival of liver cancer patients.
Patients and methods

This study determined whether the combination of TCM and conventional cancer treatment affects the survival of liver cancer patients. A retrospective cohort study was conducted in 127,237 newly diagnosed liver cancer patients from 2000 to 2009 in the National Health Insurance Program database.
Results

Among these patients, 30,992 (24.36%) used TCM for liver cancer care. All patients were followed up until 2011. The mean follow-up was 5.67 years (SD 1.47) for TCM users and 5.49 years (SD 3.64) for non-TCM users. Compared with patients without TCM use, patients with TCM use were significantly associated with a decreased risk of death [hazard ratio (HR) = 0.65, 95% confidence interval (CI) = 0.64 to 0.66] with multivariate adjustment. A similar significant protective effect of TCM use across various subgroups of chronic liver diseases was also observed. Jia Wei Xiao Yao San (HR = 0.89, 95% CI = 0.81 to 0.96) and Chai Hu Shu Gan Tang (HR = 0.86, 95% CI = 0.78 to 0.95) were the most effective TCM agents that improved survival.
Conclusions

This cohort study provided information that adjunctive therapy with TCM may improve the survival in liver cancer patients. Further studies are needed to confirm the potential role of TCM in HCC.

This article is protected by copyright. All rights reserved.

StephenW

辅助中国传统中医治疗改善肝癌患者的生存期

    岳祥Liao1,2，成杰Lin3,4,5，薛岳，周Lai4,6，仁怀Chiang7,8,9，Jaung耿琳，* andTsai涌Li8,9,10，*

DOI：10.1111 / liv.12847

这篇文章是受版权保护的。版权所有。

问题
封面图片的卷。 35第5期
肝国际


    中国医药，中国医药大学，台湾台中的1学校
    2学校中国医学专上文凭，义守大学，台湾高雄
    家庭医学科，中国医学大学附设医院，台中，台湾3部
    医学，医学院，中国医科大学，台中，台湾4学校
    医学研究，中国医科大学附属医院，台中，台湾5系
    6部Hepatogastroenterology的，内科，中国医科大学附属医院，台中市，台湾
    健康数据，中国医科大学附属医院，台中市，台湾7管理办公室
    8研究中心中国医药针灸，中国医药大学，台湾台中
    生物统计学中国医科大学9研究所，台湾台中
    医疗管理，医疗学院和健康科学，亚洲大学，台中，台湾10处

*通讯作者：蔡涌李Jaung-庚霖
中国医科大学，薛岳，施路91号，台中，40402台，电话：886-4-2205-3366分机。 6605，传真：886-4-2207-8539，电子邮件：[email protected]

    这篇文章已被接受发表，并接受全面的同行评审，但经过审稿，排版，分页和校对过程中，这可能会导致这个版本和记录的版本之间的差异一直没有。请引用这篇文章的DOI：10.1111 / liv.12847

抽象
背景

中国传统医药（TCM）是癌症刺激了对肝癌细胞毒活性宿主免疫反应的作用的替代治疗。没有研究评估中医治疗对肝癌患者的生存期。
患者和方法

本研究确定医药和常规癌症治疗的组合是否影响肝癌患者的生存。回顾性队列研究是在127237新诊断的肝癌患者在国民健康保险数据库进行了2000年至2009年。
结果

在这些患者中，30,992（24.36％），使用中医肝癌治疗。所有患者进行随访，直到2011年，平均随访为5.67年（SD 1.47），中药用户和5.49年（SD 3.64），非TCM用户。与患者没有使用TCM相比，患者使用中医进行显著死亡[危险比（HR）= 0.65，95％置信区间（CI）= 0.64〜0.66]的风险降低与多元调整有关。也有人跨越慢性肝病各小组TCM使用类似显著的保护作用。佳伟逍遥散（HR = 0.89，95％CI = 0.81〜0.96），柴胡叔甘汤（HR = 0.86，95％CI = 0.78〜0.95）是最有效的中药制剂是提高生存率。
结论

本队列研究提供的资料辅助治疗中医可改善肝癌患者的生存期。还需要进一步的研究来证实中医药在肝癌的潜在作用。

无忌抗病毒

柴胡配方制剂确实有效！可缓解很多不适症状，自身多年验证。